ATRC vs. ATEC, OFIX, SRDX, IART, CATX, AORT, MDXG, SILK, ATRI, and EMBC
Should you be buying AtriCure stock or one of its competitors? The main competitors of AtriCure include Alphatec (ATEC), Orthofix Medical (OFIX), Surmodics (SRDX), Integra LifeSciences (IART), Perspective Therapeutics (CATX), Artivion (AORT), MiMedx Group (MDXG), Silk Road Medical (SILK), Atrion (ATRI), and Embecta (EMBC). These companies are all part of the "surgical & medical instruments" industry.
AtriCure (NASDAQ:ATRC) and Alphatec (NASDAQ:ATEC) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, dividends, valuation, profitability, risk, community ranking, analyst recommendations, media sentiment and institutional ownership.
AtriCure presently has a consensus target price of $49.78, indicating a potential upside of 116.80%. Alphatec has a consensus target price of $22.89, indicating a potential upside of 120.72%. Given Alphatec's higher probable upside, analysts plainly believe Alphatec is more favorable than AtriCure.
AtriCure received 233 more outperform votes than Alphatec when rated by MarketBeat users. Likewise, 68.98% of users gave AtriCure an outperform vote while only 56.68% of users gave Alphatec an outperform vote.
AtriCure has a net margin of -8.98% compared to Alphatec's net margin of -37.45%. AtriCure's return on equity of -7.85% beat Alphatec's return on equity.
In the previous week, Alphatec had 1 more articles in the media than AtriCure. MarketBeat recorded 6 mentions for Alphatec and 5 mentions for AtriCure. AtriCure's average media sentiment score of 1.81 beat Alphatec's score of 0.62 indicating that AtriCure is being referred to more favorably in the media.
AtriCure has higher earnings, but lower revenue than Alphatec. AtriCure is trading at a lower price-to-earnings ratio than Alphatec, indicating that it is currently the more affordable of the two stocks.
99.1% of AtriCure shares are owned by institutional investors. Comparatively, 66.4% of Alphatec shares are owned by institutional investors. 3.2% of AtriCure shares are owned by company insiders. Comparatively, 22.8% of Alphatec shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
AtriCure has a beta of 1.41, meaning that its share price is 41% more volatile than the S&P 500. Comparatively, Alphatec has a beta of 1.48, meaning that its share price is 48% more volatile than the S&P 500.
Summary
AtriCure beats Alphatec on 9 of the 17 factors compared between the two stocks.
Get AtriCure News Delivered to You Automatically
Sign up to receive the latest news and ratings for ATRC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ATRC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
AtriCure Competitors List
Related Companies and Tools
